1257TiP - KEYNOTE 029: Phase 1/2 randomized study of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma
| Autor: | Atkins, M.B., Carlino, M.S., Hill, A.G., McNeil, C.M., Ribas, A., Atkinson, V., Cebon, J.S., Jameson, M.B., Hwu, W.-J., Thompson, J.A., Anderson, J., Homet Moreno, B., Ibrahim, N., Long, G.V. |
|---|---|
| Zdroj: | In Annals of Oncology September 2017 28 Supplement 5:v446-v446 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|